APC.V · Advanced Proteome Therapeutics Corporation

-

Please sign in to comment on APC.V

1 Comment

Admin

4 years, 1 month ago

Advanced Proteome Therapeutics Corporation is currently in a long term uptrend where the price is trading 92.3% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Advanced Proteome Therapeutics Corporation's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 200.6% to $-342K since the same quarter in the previous year.

Finally, its free cash flow fell by 107.1% to $-231K since the same quarter in the previous year.

Based on the above factors, Advanced Proteome Therapeutics Corporation gets an overall score of 2/5.

ISIN	CA0076282098
Exchange	V
CurrencyCode	CAD
Sector	Healthcare
Industry	Biotechnology & Medical Research

Dividend Yield	0.0%
Market Cap	823K
PE Ratio	None
Target Price	None
Beta	1.37

ABOUT

Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.

APC.V · Advanced Proteome Therapeutics Corporation

-

Advanced Proteome Therapeutics Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Advanced Proteome Therapeutics Corporation using a moving average strategy